Aspects of Decision Making in Cost-effectiveness Modelling

Nathan Green (n.green@ucl.ac.uk) (with thanks to Gianluca Baio, Chris Jackson, Nicky J. Welton, Mark Strong, Anna Heath)

24th November 2022


Preliminaries

University College London



- UCL was rated 2nd in the UK for research power in the Research Excellence Framework 2021
- UCL is ranked 8th in the 2022 QS World University Rankings
- The Department of Statistical Science has played a major role in the development of the subject ever since its foundation in 1911 as the Department of Applied Statistics

Objectives



- Introduction to Health economics modelling
 - Decision trees
 - Markov models
- Introduction to sensitivity analyses
 - Deterministic
 - ★ One-way & multi-way
 - ★ Scenario
 - Probabilistic

Objectives

Computer practicals



- Emphasis on practical examples
 - Decision tree and Markov models
 - using R programming language

Timetable

- 0:00-1:00 Health Economics modelling lecture
- 1:00 1:45 Decision tree and Markov model practical
- BREAK
- 1:50 2:20 Sensitivity analysis
- 2:20-3:00 Sensitivity analysis practical

More Bayesian Health Economics...



- This course is only a small part of an annual week-long summer school
 - usually in Florence, Italy
- Several books available
- Edition two of BCEA book in the pipeline and a Health Economic in R book close to being finished!

Lecture 2

Uncertainty analysis

Summary

- Health economic evaluation
 - ▶ What is health economics?
 - Why do we need health economics?
- A framework for health economic evaluation
 - Statistical modelling
 - ► Economic modelling
 - Decision analysis
 - Uncertainty analysis
- Standard vs Bayesian HTA
 - ► Two-stage vs integrated approach
- Decision-making
 - Cost-effectiveness plane
 - ▶ ICER
 - EIB

References


Bayesian Methods in Health Economics, chapter 1.
Baio et al (2017). Bayesian Cost-Effectiveness Analysis with the R package BCEA



Parameters








Model structure

Old chemotherapy



New chemotherapv $_{A_1}$



Decision analysis


Old chem	otherapy
Benefits	Costs

New chen	notherapy
Benefits	Costs

Parameters



Decision analysis




0.5 1.0 1.5 2.0

0 2000 6000



Old chemotherapy	
Benefits	Costs
741	670 382.1

0.2 0.4 0.6 0.8 1.0 hosp




New chemotherapy	
Benefits	Costs
732	1 131 978

Parameters








Model structure

Old chemotherapy



New chemotherapv $_{A_1}$



Decision analysis

Old chemotherapy	
Benefits	Costs
741	670 382.1
699	871 273.3

New chemotherapy	
Benefits	Costs
732	1 131 978
664	1 325 654


4. Uncertainty analysis

$[p(\boldsymbol{\theta} \mid e, c) \text{ vs } g_i(\theta_i)]$

Parameters







Model structure

Old chemotherapy



New chemotherapv



Decision analysis

Old chemotherapy	
Costs	
670 382.1	
871 273.3	
425 822.2	
790 381.2	

New chemotherapy	
Benefits	Costs
732	1 131 978
664	1 325 654
811	766 411.4
774 5	1 066 840 8

$$ICER = \frac{276468.6}{58.3}$$
$$= 6497.1$$



Is this all we need? (see Vol)

- The CEAC only deals with the probability of making the "right decision"
- But it does not account for the payoff/penalty associated with making the "wrong" one!



Is this all we need? (see Vol)

• The CEAC only deals with the probability of making the "right decision"

- But it does not account for the payoff/penalty associated with making the "wrong" one!
- **Example 1**: Intervention t = 1 is the most cost-effective, given current evidence
 - $ightharpoonup \Pr(t=1 \text{ is cost-effective}) = 0.51$
 - If we get it wrong: Increase in costs = £3Decrease in effectiveness = 0.000001 QALYs
 - ► Large uncertainty/negligible consequences ⇒ can afford uncertainty

- The CEAC only deals with the probability of making the "right decision"
- But it does not account for the payoff/penalty associated with making the "wrong" one!
- **Example 1**: Intervention t = 1 is the most cost-effective, given current evidence
 - ▶ Pr(t = 1 is cost-effective) = 0.51
 - ▶ If we get it wrong: Increase in costs = £3

 Decrease in effectiveness = 0.000001 QALYs
 - ► Large uncertainty/negligible consequences ⇒ can afford uncertainty
- Example 2: Intervention t=1 is the most cost-effective, given current evidence
 - ▶ Pr(t = 1 is cost-effective) = 0.999
 - ► If we get it wrong: Increase in costs = £1 000 000 000

 Decrease in effectiveness = 999999 QALYs
 - ► Tiny uncertainty/dire consequences ⇒ probably should think about it...